


Journal Pre-proof

Functional characterization of the *SDR42E1* reveals its role in vitamin D biosynthesis

Nagham Nafiz Hendi, Maria Teresa Bengoechea-Alonso, Johan Ericsson, Georges Nemer



PII: S2405-8440(24)12497-8

DOI: <https://doi.org/10.1016/j.heliyon.2024.e36466>

Reference: HLY 36466

To appear in: *HELIYON*

Received Date: 11 July 2024

Accepted Date: 15 August 2024

Please cite this article as: Functional characterization of the *SDR42E1* reveals its role in vitamin D biosynthesis, *HELIYON*, <https://doi.org/10.1016/j.heliyon.2024.e36466>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Ltd.

1 **Functional characterization of the *SDR42E1* reveals its role in vitamin D**
2 **biosynthesis**

3 **Nagham Nafiz Hendi^{1,2,3}, Maria Teresa Bengoechea-Alonso¹, Johan Ericsson¹, and Georges Nemer^{2,4*}**

4 ¹ Division of Biological and Biomedical Sciences, and ² Division of Genomics and Translational Biomedicine, College
5 of Health and Life Sciences, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar; pericsson@hbku.edu.qa;
6 MAlonso@hbku.edu.qa.

7 ³ Systems Biology and Immunology Department, Sidra Medicine, Doha P.O. Box 26999, Qatar; nhendi@sidra.org,
8 ORCID:0000-0003-2737-0565.

9 ⁴ Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut P.O. Box 110236,
10 Lebanon.

11 * Correspondence:

12 Georges Nemer, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar; email:
13 gnemer@hbku.edu.qa; Tel.: +974-445-41330; ORCID: 0000-0003-2157-5279.

14 **Highlights**

- 15 • SDR42E1 knockout alters key vitamin D synthesis regulators: EBP, DHCR7, ALPP, and CYP26A1.
- 16 • Multi-omics reveal SDR42E1's broad role in steroid synthesis and lipid metabolism.
- 17 • SDR42E1 knockout accumulates 7-dehydrocholesterol, hindering vitamin D production.
- 18 • SDR42E1 variant presents a promising target for addressing vitamin D deficiency.

19 **Abstract**

20 Vitamin D deficiency poses a widespread health challenge, shaped by environmental and genetic determinants. A
21 recent discovery identified a genetic regulator, rs11542462, in the *SDR42E1* gene, though its biological implications
22 remain largely unexplored. Our bioinformatic assessments revealed pronounced *SDR42E1* expression in skin
23 keratinocytes and the analogous HaCat human keratinocyte cell lines, prompting us to select the latter as an
24 experimental model. Employing CRISPR/Cas9 gene-editing technology and multi-omics approach, we discovered
25 that depleting *SDR42E1* showed a 1.6-fold disruption in steroid biosynthesis pathway (P -value = 0.03), considerably
26 affecting crucial vitamin D biosynthesis regulators. Notably, *SERPINB2* (P -value = 2.17×10^{-103}), *EBP* (P -value =
27 2.46×10^{-13}), and *DHCR7* (P -value = 8.03×10^{-09}) elevated by ~2-3 fold, while *ALPP* (P -value < 2.2×10^{-308}),
28 *SLC7A5* (P -value = 1.96×10^{-215}), and *CYP26A1* (P -value = 1.06×10^{-08}) downregulated by ~1.5-3 fold. These
29 alterations resulted in accumulation of 7-dehydrocholesterol and reduction of vitamin D production, as evidenced by
30 the drug enrichment (P -value = 4.39×10^{-06}) and vitamin D quantification ($R^2 = 0.935$, P -value = 0.0016) analyses.
31 Our investigation unveils *SDR42E1*'s significance in vitamin D homeostasis, emphasizing the potential of precision
32 medicine in addressing vitamin D deficiency through understanding its genetic basis.

33 **Keywords**

34 *SDR42E1*; Vitamin D biosynthesis; Steroidogenesis; CRISPR/Cas9; Multi-omics; HaCat.

35 1. Introduction

36 Vitamin D deficiency, characterized by suboptimal 25-hydroxyvitamin D (25(OH)D) levels below 20 ng/mL (50
37 nmol/L), represents a widespread nutritional deficiency linked to critical health conditions, including osteoporosis and
38 rickets. The intricate interplay of genetic determinants substantially influences serum 25(OH)D concentrations, with
39 twins and familial studies revealing notable variations ranging from 23% to 90% [1]. The prevalence of vitamin D
40 deficiency in regions with abundant sunlight, such as the Middle East and North-Africa (MENA) region, emphasizes
41 the relevance of genetic determinants [2]. However, the complex pathways and involvement of multiple genes in
42 vitamin D synthesis hinder our comprehensive understanding of the genetic contribution to 25(OH)D variation.

43 Recent genome-wide association studies (GWAS) have provided crucial insights into the genetic architecture of
44 25(OH)D, identifying single-nucleotide polymorphisms (SNP) statistically linked to 25(OH)D levels [3]. One notable
45 variant is identified in the novel, uncharacterized human short-chain dehydrogenase/reductase family 42E, member 1
46 (*SDR42E1*) on chromosome 16q23 in exon 3, a genomic locus that has received limited attention. This variant,
47 identified as rs11542462 in the SNP database, introduces a premature stop codon, resulting in the substitution of amino
48 acids, specifically Glutamine, with termination at position 30 of the protein (p.Q30* GLN>*TER). This mutation
49 potentially leads to a non-functional *SDR42E1* enzyme [4-6].

50 *SDR42E1* is a member of the extended short-chain dehydrogenase/reductase superfamily with a broad substrate
51 specificity and potential involvement in lipid metabolism [7]. Although its precise function remains uncertain, the
52 protein is implicated in regulating cellular processes and may impact steroid synthesis through proposed roles as an
53 oxidoreductase and steroid delta-isomerase, potentially utilizing nicotinamide adenine dinucleotide phosphate
54 (NAD(P)(H)) [8, 9]. Interestingly, numerous genetic investigations highlight a close interrelation between *SDR42E1*
55 and the regulation of steroid hormone biosynthesis [10, 11]. Given the potential importance of this gene, further
56 investigation is crucial to elucidate the structure, biological function, and impact of *SDR42E1* mutations on human
57 health.

58 The nonsense variant in *SDR42E1* has been associated with serum concentrations of vitamin D precursor, 8-
59 dehydrocholesterol (8-DHC) [12]. This steroidal compound demonstrates a close relationship with a crucial precursor
60 in vitamin D synthesis, namely 7-dehydrocholesterol (7-DHC), both of which accumulate in patients affected by
61 Smith-Lemli-Opitz syndrome [13, 14]. Our previous research on *in silico* characterization of the *SDR42E1* identified
62 potential substrates of the protein as 8-DHC, 7-DHC, and 25(OH)D [8]. In this study, we expand those findings to a

63 comprehensive profiling of *SDR42E1* functions using a multi-disciplinary approach, integrating bioinformatic
64 analysis with the use of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated
65 protein 9 (Cas9) gene-editing technology to mimic the *SDR42E1* nonsense variant in the selected human keratinocyte
66 HaCat cell line.

67 **2. Methods**

68 **2.1. *In silico* bioinformatics analyses**

69 The expressions of quantitative trait loci (eQTLs) of *SDR42E1* in normal and cancer human tissues were explored
70 through Genotype-tissue Expression (GTEx, <http://commonfund.nih.gov/GTEx/>). The All RNA-sequencing and
71 Combining Chromatin Immunoprecipitation-sequencing (ChIP-seq) Sample Search Space (ARCHS4) database was
72 also used to assess the expression map of *SDR42E1* in cells and tissues, which contains data on 187,964 human and
73 mouse samples, as previously described [15].

74 **2.2. Cell culture**

75 The human immortalized skin keratinocyte, HaCat (CRL-2309, Research Resource Identifier (RRID): CVCL_0038),
76 and human embryonic kidney cell lines, HEK293T (CRL-3216), were obtained from the American Type Culture
77 Collection (ATCC, Manassas, VA, United States) or generously provided by collaborators.

78 Cells were seeded in T75 tissue culture flasks (Sigma-Aldrich, United States) and cultured in Dulbecco's modified
79 Eagle's medium (DMEM) with (4.5 g/L) high D-Glucose, (2 mM) Glutamine, and (1 mM) Sodium Pyruvate,
80 supplemented with 10% fetal bovine serum (FBS) and (1X) antibiotic-antimycotic (Thermo Fisher Scientific Gibco,
81 United States). To prevent contamination, the medium was changed every other day. At 70% to 80% confluency, all
82 cells were harvested through treatment with 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich).
83 The cell pellets were subsequently rinsed once with sterile (1X) Dulbecco's phosphate-buffered saline (DPBS; Gibco),
84 underwent centrifugal precipitation at 900 revolutions per minute (rpm) for 3 minutes, and passaged at a 1:6 ratio. All
85 cell lines were grown under sterile conditions in a monolayer culture at 37°C, with a 5% CO₂ atmosphere and 95% air
86 humidity.

87 **2.3. Plasmid construction and single guide RNA cloning**

88 To generate a single-cell-derived *SDR42E1* knockout through CRISPR/Cas9 technology, GenScript (United States)
89 designed single guide RNA (sgRNA) targeting exon 3 of the human *SDR42E1* gene, proximate to the p.Q30*
90 GLN>*TER premature stop codon mutation, as illustrated in Figure S2 a. These sgRNAs were synthesized by

91 Integrated DNA Technologies (IDT, United States) with overhangs complementary to the BsmBI-digested plasmid
92 (sgRNAs-*SDR42E1*, Table S1). After the BsmBI digestion and filler fragment excision using GeneJET Gel Extraction
93 Kit (Thermo Scientific, United States), the sgRNA guide sequences were integrated into the BsmBI site of the
94 LentiCRISPR v2-Puro-U6 vector (a gift from Feng Zhang, RRID: Addgene_52961; <http://n2t.net/addgene:52961>,
95 Addgene plasmid, United States) according to a corresponding Addgene protocol with minor modifications [16].
96 Briefly, oligonucleotides for the sgRNA-*SDR42E1* were annealed through heating to 95 °C for 5 minutes and gradual
97 cooling to 25 °C. Subsequently, they were phosphorylated using T4 Polynucleotide Kinase (New England Biolabs,
98 United States) at 37 °C for 30 minutes and inactivated at 70 °C for 10 minutes. The annealed oligonucleotides were
99 cloned into the digested lentiCRISPR v2 backbone using T4 DNA ligase (Invitrogen, United States) at 16 °C
100 overnight. The three obtained CRISPR/Cas9 constructs were amplified in Stbl3 chemically competent *Escherichia*
101 *coli* (C737303, Invitrogen) through heat shock transformation and cultured in Super Optimal Broth Culturing medium
102 (SOC, Invitrogen) for 1 hour. Positive colonies were purified from (100 µg/mL) ampicillin-supplemented-LB media
103 using QIAprep Spin Miniprep (Qiagen, Germany). The insertion of the sgRNA cassette was confirmed for several
104 colonies through colony polymerase chain reaction (PCR) validation and DNA Sanger sequencing using the human
105 U6 Forward primer (U6 for Lenti-CRISPRv2, Table S1). The most efficient sgRNAs were selected for the *SDR42E1*
106 knockout experiments, namely sgRNA2-*SDR42E1* and sgRNA3-*SDR42E1* (Figure S2 b). Non-targeting lentiCRISPR
107 v2 plasmid (an empty vector) served as a negative control.

108 **2.4. Lentiviral production**

109 HEK293T cells, leveraging the crucial Simian Virus 40 (SV40) large T-antigen for viral vector production, were
110 transiently transfected with non-targeting and *SDR42E1*-targeting CRISPR/Cas9 plasmids to produce lentiviral
111 particles (LVPs). Briefly, HEK293T cells were seeded in a 10-cm petri dish (Sigma-Aldrich) for 20-24 hours. Cells
112 were then supplemented with DMEM containing 10% Bovine serum (Gibco) and treated with (25 mM) chloroquine
113 (Cayman, United States) to enhance LVP stability and transfection efficiency. At 65-70% confluency, co-transfection
114 of (12 µg) lentiviral DNA constructs with lentivirus packaging mix (Dharmacon, TLP4606, United States) was
115 executed using calcium phosphate precipitation as described previously [17]. At 6 hours of incubation at 37 °C, culture
116 media was changed to standard culture medium, and cells were incubated for at least 72 hours to achieve high-titer
117 virus production. Afterward, the viral supernatant was harvested, filtered through 0.45-µm sterile low protein binding
118 filters (Millipore, Sigma-Aldrich), and frozen at -80°C in small aliquots, being freshly thawed for each infection cycle.

119 **2.5. Generation of CRISPR/Cas9-mediated *SDR42E1*-edited cells**

120 The targeted HaCat cells were infected with viruses generated from each CRISPR/Cas9-sgRNA construct at a
121 multiplicity of infection (MOI) of 5 in 6-well plates (Sigma-Aldrich), in the presence of (10 µg/mL) polybrene to
122 induce sgRNA expression. After 24 hours of transduction at 37°C, puromycin (A1113803, Thermo Fisher Scientific)
123 was applied at a concentration of 2-5 µg/mL for approximately 7 days to eliminate non-transduced cells. Cells were
124 then harvested at 80% confluency for DNA and mRNA extractions to verify the gene editing efficiency.

125 The array dilution method, a robust isolation technique, was utilized to generate a monoclonal homozygous *SDR42E1*
126 gene-edited cell line from a polyclonal pool of heterozygous cells. Infected cells were isolated and sorted into single
127 clones in a 96-well plate through a 2-fold serial dilution, first vertically, and then horizontally. Three to four weeks
128 post-infection, individual cell clones were verified for genome editing efficiency and genotyping using T7
129 endonuclease 1 (T7E1) assay, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), Sanger
130 sequencing, and Western blotting. The top gene-edited clone, exhibiting homozygous knockout, was selected for
131 further investigations into gene function and expression.

132 **2.6. T7 endonuclease 1 mismatch assay**

133 The efficiency of CRISPR/Cas9-mediated gene-editing of the designed sgRNAs was validated through a T7E1 assay,
134 as per the instructions, which recognizes and cleaves non-perfectly matched DNA. Genomic DNA was extracted from
135 infected HaCat cells using Quick Extract Genomic DNA buffer (A560001, AMPLIQON, Denmark), following the
136 manufacturer's protocol. After DNA quantification, the sgRNA genomic target site in *SDR42E1* exon 3 was PCR-
137 amplified with high-fidelity AccuPrime Taq DNA polymerase (NEB 2U/uL, Thermo Scientific) using primers
138 flanking the target site (T7-*SDR42E1*, Table S1) and purified with a GeneJET PCR purification kit (Thermo
139 Scientific). The PCR amplicons (200 ng) were denatured and reannealed to form heteroduplexes DNA, followed by
140 digestion with T7E1 enzyme (M0302L, New England Biolabs) at 37°C for 30 minutes. The digested products were
141 run on a 2% agarose gel at 90 volts for 40 minutes to verify the size and specificity of the products. Control samples,
142 including empty lentiCRISPR vector and non-T7 digested-genomic samples, were used for result validation.

143 **2.7. DNA sequencing**

144 To determine the exact genotype of the CRISPR/Cas9-mediated *SDR42E1* gene-editing, Sanger sequencing of the
145 purified PCR product of genomic DNA was conducted by MacroGen Inc. (<http://macrogen.com>, Korea), using the
146 forward T7-*SDR42E1* primer (T7-*SDR42E1*, Table S1). For mutation identification, the obtained sequences were

147 aligned to the human genomic reference sequence of *SDR42E1* from Ensembl (ENST00000328945) and compared to
148 a non-targeting lentiCRISPR vector control using Snapgene version 5.3.2 (GSL Biotech LLC; Chicago, IL, United
149 States).

150 2.8. Cell lysis and Western blot of immunoprecipitation

151 To confirm the loss of protein expression in *SDR42E1* gene-edited cells, washed cells were lysed using ice-cold
152 radioimmunoprecipitation assay (RIPA) buffer, supplemented with (1 mM) phenylmethylsulfonyl fluoride (PMSF),
153 (1M) dithiothreitol (DDT), and a protease inhibitor cocktail (UD282713, Thermo Fisher Scientific). After a 30-minute
154 incubation at 4°C with rotation, the lysates were centrifuged at 10,000 ×g for 15 minutes at 4°C. The supernatants
155 were stored at -80°C until analysis. Protein concentration was determined photometrically using a bicinchoninic acid
156 (BCA) protein assay kit (Pierce, Thermo Fisher Scientific).

157 Whole-cell extracts were pre-incubated with the desired antibody, anti-SDR42E1 rabbit monoclonal antibody
158 (Thermo Fisher Scientific Cat# PA5-53156, RRID: AB_2647060, 1:500 dilution), overnight with gentle rotation at 4
159 °C to generate specific immunocomplex. Protein samples were then incubated with protein A/G magnetic beads
160 (Pierce, 88802, Thermo Scientific) for 2 hours with gentle rotation at 4 °C. After a brief centrifugation at 3000 rpm
161 for 30 seconds to pellet the magnetic beads with bound immunocomplexes, they were placed in a magnetic separation
162 rack and the supernatant was discarded. Magnetic beads were briefly spun down with the bound immunocomplexes
163 at 3000 rpm for 30 seconds, and subsequently placed in a magnetic separation rack and the supernatant. The pellet
164 underwent three washes with ice-cold RIPA buffer and was finally denatured in 5X SDS-sample buffer at 37 °C for
165 30 minutes.

166 An equal quantity of protein lysates was electrophoresed on a precast Novex NuPAGE 4-12% Bis-Tris SDS-
167 polyacrylamide gel using the XCell SureLock electrophoresis system (Invitrogen). Resolved proteins were wet-
168 transferred to a nitrocellulose membrane (Millipore) using a Trans-Blot Turbo transfer system (BioRad). After 1-hour
169 blocking with 5% bovine serum albumin (BSA, Tocris, United Kingdom) buffer at room temperature, the membrane
170 was then immunoblotted using an anti-SDR42E1-tag rabbit monoclonal antibody (1:500 dilution, WG3329739B,
171 Invitrogen) for 3 days at 4 °C in 5% BSA buffer. Beta-actin levels were determined as loading controls using a
172 monoclonal anti-beta-actin mouse antibody (1:5000 dilution, Sigma-Aldrich Cat# A5441, RRID: AB_476744).
173 Following six washes with 1X Tris Buffered Saline with Tween 20 (TBST), membranes were visualized under
174 chemiluminescence using peroxidase IgG fraction monoclonal anti-mouse IgG (H+L) secondary antibody HRP

175 conjugate (1:5000 dilution, Thermo Fisher Scientific Cat# 62-6520, RRID: AB_2533947) or anti-rabbit IgG light
176 chain specific (1:5000 dilution, Jackson ImmunoResearch Labs Cat# 211-032-171, RRID: AB_2339149, United
177 Kingdom) with Pierce ECL Western blotting substrate (32106, Thermo Scientific).

178 **2.9. RNA extraction and RT-qPCR**

179 To assess the mRNA expression in the *SDR42E1*-edited cells, total RNA was isolated from cell lines using 1 mL
180 TRIzol reagent (Invitrogen) according to the manufacturer's guidelines. RNA quantity and integrity were evaluated
181 spectrophotometrically by a NanoDrop 8000 (ND-8000-GL, Thermo Scientific) and agarose gel electrophoresis.
182 Subsequently, 2 µg of total RNA were reverse transcribed into complementary-DNA (cDNA) using the High-capacity
183 cDNA reverse transcriptase kit (Applied Biosystems, United States) following the recommendations.

184 For human gene expression analysis, each 20 µL RT-qPCR reaction utilized 5 µL of the 1:5 diluted cDNA on a Quant
185 Studio 6 Flex System (Thermo Fisher Scientific) with PowerUp SYBR Green Master Mix (Applied Biosystems).
186 Primers designed to amplify target genes are presented in Table S1. The thermal cycling conditions included a
187 denaturation step at 95°C for 10 minutes, followed by 50 cycles at 95°C for 15 seconds and 60°C for 1 minute,
188 concluding with a melt curve analysis. The housekeeping gene human beta-ACTIN served as an internal control to
189 normalize variations in total RNA expression levels across each sample. Relative mRNA expression levels were
190 assessed through comparative threshold cycle (CT) analysis, and the fold changes were calculated by the $2^{-\Delta\Delta CT}$ (delta-
191 delta cycle threshold) method, referencing the average ΔCT value of wild-type controls and reference genes [18].

192 **2.10. RNA sequencing**

193 To identify differentiated genes in the relevant pathway, equivalent amounts of high-quality RNA pools (100–200 ng)
194 were precipitated in a 75% ethanol solution and shipped to MacroGen Inc. (<http://macrogen.com>, Korea) for total
195 RNA-sequencing library construction and next-generation sequencing. In summary, the RNA sequencing libraries
196 were prepared with the TruSeq Stranded Total RNA Library Prep Kit (1000000040499, Illumina), following the
197 instructions. Following PCR enrichment, the libraries were quality-checked and quantified before sequencing on the
198 Illumina NovaSeq 6000 platform, yielding 101 bp paired-end reads. Raw sequence reads were trimmed to eliminate
199 contaminant DNA, PCR duplicates, and adaptor sequences. Reads with a quality below Q20 were filtered using CLC
200 Genomics Workbench version 22.0.2 software. The same software was employed for the assembly and alignment of
201 all paired-end reads against the latest version of the human genome (*Homo sapiens*, GRCh38). Genes with average
202 raw counts below 10 were excluded.

203 Differential expression of the genes (DEG) between control and knocked-out samples was defined as significant if the
204 expression change was ≥ 2 -fold, accompanied by an adjusted P -value < 0.05 . This assessment was conducted and
205 visualized using the R package DESeq2 version 1.34 with default parameters [19]. For gene expression heatmaps
206 based on RNA-sequencing data, \log_2 of the fold-change maximum likelihood estimate (lfcMLE) values, and $-\log_{10}$ of
207 false discovery rate (FDR, an adjusted P -value) values were used and visualized by R package pheatmap version 1.0.2.
208 The Pathview R package was used to visualize Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of
209 related genes [20].

210 We conducted Gene Set Enrichment (GSE) analysis as outlined in previous descriptions [21], against *Homo sapiens*
211 gene sets from the Enrichment map with gene lists in descending order based on lfcMLE, the unshrunk \log_2 fold
212 change generated by DESeq2. Functional annotation analyses were performed using the R package ClusterProfiler
213 version 4.2.2, an enrichment analysis tool renowned for its comprehensive visualization capabilities that offers
214 detailed insights into the collective functions of the input genes, encompassing Gene ontology (GO), KEGG, and
215 enrichment analyses with default settings. The Drug Signatures Database for Gene Set Analysis (DSigDB,
216 <http://biotechlab.fudan.edu.cn/database/drugsig/>) [22] was employed to identify candidate drugs associated with the
217 DEG. Access to DSigDB was facilitated via ClusterProfiler [23].

218 To validate the RNA-sequencing findings, RT-qPCR was performed on the same RNA extracts, targeting five
219 representative genes: *SDR42E1*, alkaline phosphatase placental (*ALPP*), solute carrier family 7A5 (*SLC7A5*), serine
220 protease inhibitor B2 (*SERPINB2*), and 7-dehydrocholesterol reductase (*DHCR7*) (Table S1). Furthermore, we
221 conducted a comparative analysis between the RNA-sequencing results from *SDR42E1* Knockout HaCat cells and
222 common genes associated with Vitamin D traits in the NHGRI-EBI GWAS Catalog (EFO_0004631) with a statistical
223 significance threshold of P -value $< 5.0 \times 10^{-8}$, as released on January 09, 2024, and accessed on January 27, 2024
224 [24]. To enhance the robustness of our analysis, we also examined genetic markers located within a 250-kilobase
225 region upstream and downstream of the reported GWAS signals, thereby enabling a comprehensive identification of
226 significant variants associated with vitamin D.

227 **2.11. Proteomics**

228 Following the whole-cell extraction procedure mentioned earlier, protein samples underwent preparation through
229 incubation at 37°C for 30 minutes. Subsequently, 50 μg of each protein sample, encompassing six samples from three
230 biological replicates of homozygous *SDR42E1* knockout and HaCat controls, was loaded onto a precast Novex

231 NuPAGE 4-12% Bis-Tris SDS-polyacrylamide gel and run at 100-voltage for approximately 60 minutes. For protein
232 band visualization, PageBlue Protein Staining Solution was applied overnight at 4°C, followed by a 10-minute wash
233 with sterilized distilled water. Each gel lane was individually cut, placed in tubes, and kept at 4°C for further mass
234 spectrophotometry analysis, as detailed previously [25].

235 Briefly, dithioerythritol and s-carbamidomethylation with iodoacetamide were included as reducing agents before in-
236 gel tryptic digestion. Following gel piece washing, sequencing-grade modified porcine trypsin was added for
237 rehydration and incubated overnight at 37°C. Extracted and desalted peptides were loaded onto a nanoflow UPLC
238 system and separated using a gradient elution solvent. The resulting peptides were then analyzed using an Orbitrap
239 Fusion Tribrid mass spectrometer (Thermo Scientific). Relative protein abundance was calculated using precursor ion
240 areas from non-conflicting unique peptides. Data analysis was then conducted using Progenesis QI (Version 2.2.,
241 Waters), Mascot Daemon (version 2.6.0, Matrix Science), and R packages Limma (Linear Models for Microarray
242 Data) version 3.56.2. Benjamini–Hochberg approach was used to convert Student’s t-tests-derived *P*-values to
243 multiple test-corrected *q*-values, with a cut-off of <0.05. Enrichment analysis and functional annotations were
244 performed for the ranked genes based on Limma-generated *P*-values against *Homo sapiens* protein set using
245 ClusterProfiler with standard settings.

246 **2.12. Vitamin D quantification**

247 Vitamin D concentrations in the cell lysates of *SDR42E1* knockouts and wild-type HaCat cells were measured using
248 a Human Vitamin D Enzyme-linked Immunosorbent Assay (ELISA) kit (MY BIOSOURCE, MBS735897, USA)
249 following the manufacturer's instructions. Cell lysates were prepared by trypsinization, 3 times ultrasonication, and
250 centrifugation at 1000×*g* for 15 minutes to remove cellular debris. The vitamin D ELISA employed a competitive
251 enzyme immunoassay on a microtitre plate coated with a polyclonal anti-vitamin D antibody, utilizing a vitamin D-
252 HRP conjugate to induce a color change inversely correlated with vitamin D levels (sensitivity: 0.1 ng/mL). Vitamin
253 D measurements were made spectrophotometrically at 450nm in a microplate reader, with triplicate samples and a
254 standard curve for interpolation.

255 **2.13. Immunofluorescence**

256 Human HaCat cells were plated on poly-L-lysine-coated coverslips in a 12-well plate. At 40-60% confluency, cells
257 were transiently transfected with 5-microgram *SDR42E1*-HA tag plasmids (RRID: Addgene_55182, Addgene) using
258 Lipofectamine 3000 (2293283, Thermo Fisher Scientific) following the manufacturer’s protocol for 24 hours. After

259 fixation with 4% paraformaldehyde, cells were blocked with 5% BSA in DPBS with 0.1% Tween-20 for 60 minutes
260 at room temperature. Following three DPBS washes, cells were probed with primary antibody overnight at 4°C,
261 washed three times with DPBS, and then incubated with secondary and tertiary antibodies for 60 minutes each at room
262 temperature.

263 Primary antibodies were diluted at 1:100, including rabbit α HA-tag polyclonal antibody (SG77, Thermo Fisher
264 Scientific Cat# 71-5500, RRID: AB_2533988), mouse monoclonal anti-golgi 58K antibody (Sigma-Aldrich Cat#
265 G2404, RRID: AB_477002), HSP60 (Heat Shock Protein 60) recombinant rabbit monoclonal antibody-mitochondrial
266 marker (HSPD1-2206R, Thermo Scientific), and rabbit calreticulin-ER marker IgG polyclonal antibody (Thermo
267 Fisher Scientific Cat# PA5-80402, RRID: AB_2787722). For secondary antibodies, biotinylated goat anti-rabbit IgG
268 (H+L) antibody (65-6140, Thermo Scientific) and goat anti-rabbit IgG antibody (H+L), biotinylated (Vector
269 Laboratories Cat# BA-1000, RRID: AB_2313606) were used at a 1:250 dilution. The tertiary antibody used was
270 Streptavidin Alexa Fluor 488 conjugate at a 1:250 dilution (Molecular Probes Cat# S32354, RRID: AB_2315383).
271 Nuclei were stained with Hoechst (33258, Invitrogen) at a concentration of 1 μ g/ml, and slides were mounted with
272 ProlongTM Antifade Histomount (Thermo Fisher Scientific).

273 **2.14. Confocal microscopy**

274 Confocal microscopy was performed using a Nikon A1R confocal fluorescence microscope with a 100X oil immersion
275 objective. Specific parameters included laser excitations at 405 nm for Hoechst, 488 nm for Alexa Fluor 488, and 561
276 nm for GFP, with detector settings optimized for each fluorophore. Images were captured with consistent gain, offset,
277 and pinhole settings across all samples. Motor arm movements of 60 μ m, 0.3 mm, and 6.0 mm were utilized to ensure
278 consistent field selection. Image reconstruction and analysis were performed using Fiji-ImageJ software [26], ensuring
279 uniform treatment of all images to prevent bias.

280 **2.15. Statistical analyses**

281 Statistical analyses were performed using GraphPad Prism version 9. An unpaired or paired two-tailed Student's t-test
282 assessed significance between two groups, while Kruskal-Wallis one-way analysis of variance (ANOVA) with Dunn's
283 post hoc test was used for three or more groups. A *P*-value cutoff of 0.05 determined significance. Results were
284 presented as average \pm standard deviation or average \pm standard error of the mean (SEM). Experiments in each figure
285 utilized at least three independent biological replicates for robust and reproducible data.

286

287 3. Results

288 3.1. Bioinformatic screening reveals high *SDR42E1* expression in skin and intestinal epithelial cells

289 The GTEx database was utilized as an initial resource for analyzing the mRNA expression of *SDR42E1* across
290 different tissues under normal physiological conditions. Our analysis revealed highest expression of *SDR42E1* in sun-
291 exposed and non-exposed skin, followed by the esophagus with mean transcripts per million (TPM) values of 11.93,
292 11.62, and 5.08, respectively (Figure S1a). To explore the potential functional role of *SDR42E1* in human tissues and
293 cell lines, we evaluated its gene expression using the RNA-sequencing public resource ARCHS4. Our analysis
294 unveiled that *SDR42E1* exhibits the highest expression in intestinal epithelial cells (TPM = 8.7) and skin keratinocytes
295 (TPM = 8.4) compared to other cell types present in intestinal and skin tissues (Figure S1 b). Additionally, we observed
296 a significantly higher expression of *SDR42E1* in HaCat cells (TPM = 11.2), a spontaneously transformed aneuploid
297 keratinocyte line from adult human skin biopsies, and the HCT116 cell line (TPM = 10), a human colorectal carcinoma
298 cell line with a Kirsten rat sarcoma (*KRAS*) mutation initiated from an adult male (Figure S1 c).

299 3.2. Transcriptomic profiling identifies extensive alterations in gene expressions and pathways in 300 the *SDR42E1* knockout model

301 To investigate the function of *SDR42E1*, we targeted the surrounding region of the nonsense variant with 3 different
302 guide RNAs in HaCat cells using the LentiCRISPR v2-sgRNA system. Successful gene editing at the *SDR42E1* locus
303 was illustrated in Figure 2 a and b, affirming the efficacy of the sgRNAs. Employing the T7E1 mismatch cleavage
304 assay, we confirmed multiple homozygous and heterozygous gene edits through the detection of undigested and
305 endonuclease-digested bands (Figure S2c). Subsequently, 45 gene-edited clones were subjected to genotype validation
306 through Sanger sequencing to ascertain the specificity of the induced modifications. Interestingly, DNA sequencing
307 of Clone 32 revealed a frame-shifting insertion of a (T) nucleotide at the Cas9 cleavage site, introducing a premature
308 stop codon 30 amino acids downstream of the p.Q30* GLN>*TER mutation (Figure S2 d).

309 In parallel, to establish a comparative baseline model for validating gene-edited cells, HaCat cells were transiently
310 transfected with an in-house constructed plasmid carrying the entire coding sequence of wild-type *SDR42E1* to
311 amplify its protein expression. This augmentation was essential given the minimal endogenous expression of
312 *SDR42E1*. Wild-type *SDR42E1* protein was detected at the anticipated molecular weight of approximately 44
313 kilodalton (kDa) via Western blotting (Figure 1a), predominantly localized to the cytoplasm and cellular membrane
314 in HaCat cells (Figure 1b), excluding the mitochondria, Golgi apparatus, or endoplasmic reticulum (data not shown).

315 Subsequent Western blot analysis of immunoprecipitated SDR42E1 on Clone 32 confirmed complete loss of its
316 expression (Figure 1c), aligning with RT-qPCR results (Figure 1d). Consequently, this clone was identified as an
317 *SDR42E1* homozygous knockout and selected for further validation and functional investigations.

318 The investigation into the transcriptomic impacts of the homozygous knockout of *SDR42E1* in HaCat cells was
319 initially conducted through RNA-sequencing. Employing the R package DESeq2 for differential expression analysis,
320 5,449 DEG were identified out of 14,025 read counts in the homozygous knockout cells, exhibiting an $-\log$ of FDR
321 less than 0.05 compared to the wild-type controls (Figure 2). The principal component analysis (PCA) and
322 multidimensional scaling (MDS) plots revealed a distinct separation between the *SDR42E1* knockouts and the wild-
323 type HaCat cells (Figure 2a and b). This distinction was also evident in the heatmap displaying the expression levels
324 of the top 100 DEG (Figure 2c), with the most statistically significant mRNA observed to be downregulated, as
325 depicted in the volcano plot (Figure 2d).

326 Among the significant DEG resulting from the inactivation of *SDR42E1*, 458 were significantly upregulated, with a
327 \log_2 fold change (FC) ≥ 0.3 , including laminin subunit gamma 2 (*LAMC2*; FC = 1.60, FDR = 4.37×10^{-262}), pleckstrin
328 homology like domain family A1 (*PHLDA1*; FC = 1.93, FDR = 1.31×10^{-228}), keratin 6A (*KRT6A*; FC = 1.26, FDR
329 = 8.32×10^{-197}), keratin 18 (*KRT18*; FC = 1.36, FDR = 2.75×10^{-171}), *SERPINB2* (FC = 3.17, FDR = 2.17×10^{-103}),
330 and endothelial lipase G (*LIPG*; FC = 0.75, FDR = 7.31×10^{-68}) (Figure 2c and d). Conversely, 1,058 were
331 downregulated with a \log_2 fold change ≤ -0.3 , including *ALPP* (FC = -2.96, FDR < 2.2×10^{-308}), keratin 19 (*KRT19*;
332 FC = -1.60, FDR < 2.2×10^{-308}), DNA topoisomerase II alpha (*TOP2A*; FC = -1.29, FDR = 2.4×10^{-284}), *SLC7A5*
333 (FC = -1.54, FDR = 1.96×10^{-215}), and solute carrier family 3A2 (*SLC3A2*; FC = -1.09, FDR = 1.17×10^{-171}) (Figure
334 2c and d). Summary statistics for top RNA-sequencing data are presented in Table S2.

335 To gain deeper insights into the biological functions of DEG from the *SDR42E1* knockout model, an enrichment
336 analysis was conducted using the ClusterProfiler R package. The KEGG analysis showed that the majority of activated
337 pathways are predominantly involved in ribosome biogenesis (FC = 2.15, adjusted *P*-value = 0.0008), interleukin 17
338 (*IL-17*) signaling (FC = 1.6, adjusted *P*-value = 0.0008), immune disorders (FC = 1.6, adjusted *P*-value = 0.002),
339 cellular senescence (FC = 1.5, adjusted *P*-value = 0.004), steroid biosynthesis (FC = 1.6, adjusted *P*-value = 0.03),
340 lipid metabolism and atherosclerosis process (FC = 1.3, adjusted *P*-value = 0.04) (Figure 3a and c). On the other hand,
341 deactivated pathways are linked to glycosphingolipid biosynthesis (FC = -1.6, adjusted *P*-value = 0.004), cardiac

342 muscle contraction (FC = -1.6, adjusted P -value = 0.008), vitamins metabolism (FC = -1.6, adjusted P -value = 0.009),
343 ABC transporters (FC = -1.5, adjusted P -value = 0.04) (Figure 3a).

344 Interestingly, analysis of KEGG pathways revealed significant genetic alterations in the pathways of steroid and
345 steroid hormone biosynthesis (Figure 3b and c). This was characterized by the upregulation of emopamil binding
346 protein (*EBP*, FC = 0.50, FDR = 2.46×10^{-13}), *DHCR7* (FC = 0.42, FDR = 8.03×10^{-09}), cytochrome P450 (*CYP*),
347 such as *CYP51A1* (FC = 0.63, FDR = 1.16×10^{-27}) and *CYP27B1* (FC = 1.08, FDR = 1.11×10^{-06}) (Table S2).
348 Conversely, there was a downregulation observed in several *CYP* family genes, including *CYP26A1* (FC = -1.55,
349 FDR = 1.06×10^{-08}) and *CYP24A1* (FC = -0.26, FDR = 3.8×10^{-02}) as well as lamin B receptor (*LBR*, FC = -0.58,
350 FDR = 5.14×10^{-20}) and catechol-O-methyltransferase (*COMT*, FC = -0.23, FDR = 8.80×10^{-04}) (Table S2).

351 Drug prediction enrichment analysis of the DEG utilizing the DSigDB database, revealed therapeutic agents
352 potentially regulated by *SDR42E1*, including dinoprostone (P -value = 7.37×10^{-10}), mifepristone (P -value = $1.12 \times$
353 10^{-09}), 17-Ethynyl estradiol (P -value = 1.67×10^{-07}), vitamin D3 (P -value = 4.39×10^{-06}), and medroxyprogesterone
354 acetate (P -value = 1.56×10^{-05}) (Figure 3c and Table S3).

355 To corroborate findings derived from the RNA-sequencing analysis of *SDR42E1* knockout HaCat cells, RT-qPCR
356 analysis was performed on a selected set of five representative genes utilizing the identical RNA extracts. The RT-
357 qPCR outcomes for *ALPP*, *SDR42E1*, *SLC7A5*, *DHCR7*, and *SERPINB2* exhibited a robust concordance with the
358 RNA-sequencing data, with a substantial Spearman correlation coefficient (R^2) of approximately 0.93 when compared
359 to wild-type HaCat cells (Table 1). These findings collectively affirm the robustness and reliability of the RNA-
360 sequencing analysis conducted in this study.

361 Furthermore, we assessed the gene replication by analyzing the DEG in the *SDR42E1* Knockout HaCat RNA-
362 sequencing data with Vitamin D-related genes reported in the GWAS Catalog [24]. We successfully replicated a
363 considerable number of the common genes in our *SDR42E1* knockout dataset, identifying 65 out of 248 genes. Notable
364 instances include the low-density lipoprotein receptor (*LDLR*), endothelial lipase (*LIPG*), and involucrin (*IVL*), which
365 exhibited significant associations in the *SDR42E1* knockout data and the GWAS Catalog, with P -values ranging from
366 9×10^{-2305} to 5×10^{-08} (Table 2).

367 **3.3. *SDR42E1* knockout profoundly alters protein expressions and pathways involved in vitamin D** 368 **regulation**

369 Employing a label-free LC-MS/MS shotgun proteomics approach, we discerned a range of differentially expressed
370 proteins in the HaCat cells with homozygous *SDR42E1* knockout, totaling 138 out of 1,320 proteins (Figure 4 and
371 Table S4). In comparison to wild-type HaCat cells, the *SDR42E1* knockout cells exhibited 101 downregulated proteins
372 and 37 upregulated proteins (Figure 4a and b). Noteworthy increases were noted in SERPINB2 (molecular mass of
373 46851), keratin 17 (KRT17) (molecular mass of 48361), and SERPINB1 (molecular mass of 42742), exhibiting
374 adjusted *P*-values (q-value) of 1.90×10^{-08} , 9.91×10^{-05} , and 2.38×10^{-02} , along with \log_2 fold changes of 3.36, 1.37,
375 and 1.23, respectively (Figure 4c). Simultaneously, there were significant downregulations of SLC3A2 (molecular
376 mass = 68180), SLC7A5 (molecular mass = 55659), LIM And SH3 Protein 1 (LASP1, molecular mass = 29717) with
377 q-values of 8.41×10^{-07} , 1.88×10^{-05} , and 2.38×10^{-02} , and \log_2 fold changes of -1.54 , -1.77 , and -1.20 , respectively
378 (Figure 4c). These findings were corroborated by RNA-sequencing analysis results.

379 The GSE analysis linked a wide range of differentially expressed proteins to the activation of pathways involved with
380 the regulation of epithelial cell apoptosis (GO:1904019, FC = 1.8, adjusted *P*-value = 0.002), development of skin
381 epidermis (GO:0098773, FC = 1.7, adjusted *P*-value = 0.008), and various processes of wound healing (GO:0042060
382 and GO:0009611, FC = 1.7, adjusted *P*-value = 0.02) (Figure 4d). Moreover, numerous proteins contributed to the
383 suppression of pathways related to the formation of melanosome and pigment granules (GO:0042470 and
384 GO:0048770), cellular response to heat (GO:0034605), and various immune-related disorders (including
385 GO:0002250, GO:0002460, and GO:0002699), with FC of -1.7 and adjusted *P*-value of 0.016 (Figure 4d).

386 **3.4. *SDR42E1* knockout decreases vitamin d production in HaCat cells**

387 To evaluate the direct impact of the *SDR42E1* knockout on the levels of vitamin D in cell lysates, vitamin D ELISA
388 was conducted. These tests demonstrated a significant reduction in the vitamin D levels to 0.52-fold ($R^2 = 0.935$) in
389 the *SDR42E1* knockout samples compared with the wild-type controls, dropping from 78.18 ng/mL to 40.60 ng/mL,
390 yielding a *P*-value of 0.0016 (Figure 5).

391 **4. Discussion**

392 The widespread prevalence of vitamin D deficiency poses a significant public health concern, associated with various
393 serious illnesses. The intricate regulation of vitamin D levels is influenced by a multifaceted interplay of genetic and
394 environmental factors, such as limited sunlight exposure and malnutrition [2]. Recent GWAS research has linked a

395 new non-sense variant, rs11542462, in the uncharacterized *SDR42E1* to serum 25(OH)D levels [4-6]. The novel
396 *SDR42E1* is believed to be engaged in multiple metabolic processes that could impact lipid metabolism and steroid
397 hormone biosynthesis [8, 9]. Our study comprehensively characterizes, for the first time, the structure and function of
398 the *SDR42E1* gene and its variant, exploring the potential impact on biological processes related to vitamin D.

399 Preliminary examination of available mRNA data for *SDR42E1* from healthy subjects revealed elevated expression
400 levels in essential tissues involved in vitamin D synthesis and metabolism [27], notably in skin keratinocytes and the
401 corresponding HaCat cell line. This evidence suggests that *SDR42E1* could be instrumental in the regulation of vitamin
402 D biosynthesis in the skin. Such insights are valuable for understanding the function of *SDR42E1*, guiding the
403 development of suitable models for further investigation. Consequently, we selected the human keratinocyte HaCat
404 cell line as our model system, reflecting the primary site of vitamin D biosynthesis. This choice is vital for
405 understanding the proposed involvement of *SDR42E1* in vitamin D regulation, providing a relevant and accurate
406 context for our investigations.

407 In the characterization study, examining the subcellular localization of uncharacterized proteins provides significant
408 clues about their metabolic functions. Previous research has reported that the subcellular distribution of proteins in the
409 SDR family largely depends on their enzymatic activity, predominantly localized to mitochondria, cytoplasm, plasma
410 membrane, and endoplasmic reticulum [8, 28]. In the current research, we specifically targeted the overexpression of
411 *SDR42E1* in enriched human HaCat cell lines to delineate its subcellular distribution. Employing targeted antibodies
412 against *SDR42E1* and staining for different cellular components, we revealed a prominent localization of *SDR42E1*
413 to the plasma membrane and cytoplasm. The plasma membrane and cytosol are critical platforms for lipid and steroid
414 metabolic processes [29]. Our observation expands our comprehension of the roles of *SDR42E1* and strongly suggests
415 its potential involvement in regulating lipid metabolism within these critical cellular compartments.

416 Employing CRISPR/Cas9 technology in HaCat cells, we successfully introduced a targeted and efficient modification
417 to the *SDR42E1*, replicating the p.Q30* GLN>*TER nonsense mutation, and mimicking a functional knock-out of the
418 gene. We conducted extensive transcriptomic and proteomic profiling in the homozygous *SDR42E1* knockout and
419 wild-type HaCat cells, uncovering numerous differentially expressed proteins and gene enrichments in various
420 downstream and steroid-related pathways. Key observations were the substantial downregulation of *ALPP* and *KRT19*
421 gene expressions in the *SDR42E1* knockout model. Alkaline phosphatase (ALP) encompasses a set of enzymes,
422 encoded by four genes, with three being tissue-specific and one ubiquitous across various body tissues. ALP plays a

423 crucial role in the synthesis of cellular membrane phospholipids and in the mineralization of new bone, particularly
424 via ALPP [30]. Elevated serum ALP levels are indicative of osteomalacia, often stemming from vitamin D deficiency
425 [31]. Kover and his colleagues initially highlighted the role of ALP as a marker for vitamin D deficiency in premature
426 infants with rickets [32]. Subsequent studies have consistently shown an inverse relationship between ALP and serum
427 25(OH)D levels [33], leading to the use of increased serum ALP as a diagnostic marker for vitamin D deficiency [34].
428 Unfortunately, there is no evidence of a functional role for *ALPP* in the skin, despite its significant expression.
429 Additionally, we observed notable alterations in numerous genes previously reported in the GWAS catalog for vitamin
430 D levels [35], following the depletion of *SDR42E1* from HaCat cells. Among these DEG were key players, including
431 *LDLR*, *LIPG*, *IVL*, *CYP26A1*, and *DHCR7*, known for their involvement in diverse biological processes related to
432 vitamin D regulation, including synthesis, transport, and degradation. Furthermore, we noticed that a batch of
433 important genes, including *SERPINB2*, *SLC7A5*, *CYP3A5*, and *LBR*, underwent significant modifications in the
434 homozygous *SDR42E1* knockout model. These observations are consistent with previous studies, emphasizing the
435 potential role of the *SDR42E1* in modulating lipid and steroid metabolism, including vitamin D in skin keratinocytes
436 [36, 37].

437 Finally, our analysis of the enriched pathways has revealed a pronounced impact on the steroid biosynthesis pathway
438 following the inactivation of the *SDR42E1* gene in HaCat cells. Notably, the upregulation of key genes involved in
439 vitamin D synthesis in the skin, *EBP* and *DHCR7*, exhibit an enhanced production of 7-DHC and a consequent
440 obstruction in its conversion to vitamin D₃ in the absence of *SDR42E1* (Figure 6). This discovery aligns with our
441 earlier research, where we demonstrated the robust substrate affinity of vitamin D₃ and its precursors, 7-DHC and 8-
442 DHC, towards *SDR42E1* through *in silico* docking studies [8]. This affinity is further evidenced by the drug
443 enrichment analysis of our *SDR42E1* knockout model, which shows a significant association with vitamin D₃ therapy.
444 Moreover, other key enzymes implicated in vitamin D synthesis and absorption, notably *CYP27B1*, *CYP24A1*,
445 *COMT*, and *ABCB1*, are also significantly regulated in the absence of *SDR42E1*, further confirming a role of
446 *SDR42E1* in maintaining vitamin D homeostasis.

447 Our proteomic analysis, consistent with RNA-sequencing, demonstrated marked increases in *SERPINB2*, *KRT17*,
448 and *SERPINB1*, and decreases in *SLC3A2*, *SLC7A5*, and *LASP1* protein levels in the *SDR42E1* knockout model.
449 *SERPINB2*, encoding the plasminogen activator inhibitor-2 (PAI-2) protein, is key in regulating blood clot breakdown
450 while *SERPINB1* is an intracellular protein that shields cells from stress-induced cytoplasmic proteases [38]. A

451 previous study showed that vitamin D regulates the production of antithrombin by affecting the SERPIN proteins,
452 suggesting a new pathway for antithrombotic therapy development [39]. Furthermore, vitamin D influences
453 keratinocyte behavior and gene expression, notably *SERPIN* genes, which play a role in skin differentiation and the
454 management of skin conditions [40]. *KRT17* is also connected to various cell functions, skin disorders, and bone
455 irregularities [41, 42]. The *SLC7A5* encodes the large neutral amino acid transporter 1 (LAT1), vital for transporting
456 large neutral amino acids across cell membranes [43]. Recent studies emphasize the critical role of LAT1 in bone
457 homeostasis, regulated by the vitamin D receptor [44, 45]. Additionally, vitamin D regulates LAT1 expression in the
458 placenta, possibly aiding fetal growth in vitamin D-deficient preeclampsia through vitamin D receptor and the mTOR
459 pathways [46]. *SLC3A2*, a component of CD98 glycoprotein, is essential for skin health and osteoclast formation by
460 interacting with LAT1 and vitamin D [47]. *SLC3A2* is upregulated by estrogen, promoting colon health and vitamin
461 D synthesis, thereby preventing colorectal cancer through vitamin D receptor activation [48]. These discoveries
462 underscore the intricate role of *SDR42E1* in managing vitamin D-related pathways and health outcomes, highlighting
463 the need for further research into its specific genetic mechanisms.

464 While our research provides considerable new insights into the functional role of *SDR42E1* in vitamin D biosynthesis,
465 several areas warrant further exploration. The functions and substrates of *SDR42E1* require additional characterization
466 to fully elucidate its involvement in various biological processes, particularly in cellular senescence and DNA repair.
467 Moreover, our study did not investigate the potential interactions between *SDR42E1*, environmental factors, and
468 human diseases. This aspect could benefit from further investigation using diverse cellular and animal models, as well
469 as clinical samples. These additional studies would validate our *in vitro* findings and enhance the understanding of the
470 physiological and pathological implications of *SDR42E1* in human health.

471 In conclusion, our research has unveiled a pioneering characterization of the *SDR42E1* gene, elucidating its
472 relationship with key genes involved in steroid and vitamin D biosynthesis. This study also highlights the role of
473 *SDR42E1* in lipid metabolism, cellular aging, and DNA repair, thereby expanding our knowledge of its understanding
474 uncharacterized cellular functions.

475 **Data availability statement**

476 All data generated throughout the study have been thoroughly reviewed and included in this published article or
477 documented in the referenced data repositories. The RNA-sequencing data is accessible on the GEO database portal
478 (<https://www.ncbi.nlm.nih.gov/geo/>) under the series accession number GSE262704. Bioinformatic and statistical

479 analyses employed publicly accessible software tools, as detailed in the main text and Methods sections. For further
480 information about resources or reagents, and access to raw data and code, please contact the lead author, Georges
481 Nemer (gnemer@hbku.edu.qa), upon reasonable request.

482 **Funding**

483 Open access funding provided by the Qatar National Library.

484 **CRediT authorship contribution**

485 **Nagham Nafiz Hendi:** Writing – original draft, Visualization, Validation, Software, Investigation, Methodology,
486 Formal analysis, Data curation, Conceptualization. **Maria Teresa Bengoechea-Alonso:** Writing – review & editing,
487 Resources. **Johan Ericsson:** Writing – review & editing, Resources. **Georges Nemer:** Writing – review & editing,
488 Resources, Project administration, Supervision, Conceptualization, Funding acquisition.

489 **Declaration of competing interest**

490 The authors declare that they have no known competing financial interests or personal relationships that could have
491 appeared to influence the work reported in this paper.

492 **Acknowledgement**

493 The York Centre of Excellence in Mass Spectrometry was created thanks to a major capital investment through
494 Science City York, supported by Yorkshire Forward with funds from the Northern Way Initiative, and subsequent
495 support from EPSRC (EP/K039660/1; EP/M028127/1).

496 **Supplementary data**

497 The following are the Supplementary data to this article:

498 Supplementary Figures. Figures S1–S3.

499 Supplementary Tables.

500

Table 1 Correlation between RNA-sequencing and RT-qPCR findings in the *SDR42E1* knockout model.

Genes	RT-qPCR	RNA-Sequencing
<i>SLC7A5</i>	-1.7	-1.54
<i>ALPP</i>	-3.59	-2.96
<i>DHCR7</i>	0.27	0.42
<i>SERPINB2</i>	1.24	3.19
<i>SDR42E1</i>	-2.71	-1.15
Spearman R ²	0.93	

Spearman correlation coefficient (R²) reveals strong correlations on the log₂ (fold-change) data. Beta-actin gene was utilized as an internal control for expression normalization by geometric mean. HaCat wild-type cells were functioned as a negative control. Data present the log₂ (fold-change) of three replicates, demonstrating consistent outcomes. Abbreviations: RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

501

Table 2 Replication of DEG reported in the GWAS Catalog for vitamin D in the *SDR42E1* knockout model.

Gene	log ₂ FC	P-value	FDR	Gene Description
<i>LDLR</i>	0.979	2.297E-73	4.536E-71	Low-Density Lipoprotein Receptor; is involved in the regulation of cholesterol levels in the blood.
<i>LIPG</i>	0.749	4.168E-70	7.305E-68	Endothelial Lipase; plays a role in lipid metabolism.
<i>IVL</i>	-1.937	1.471E-50	1.517E-48	Involucrin; regulates vitamin D receptor in the epidermis.
<i>FGFBP1</i>	0.763	1.040E-46	9.656E-45	Fibroblast Growth Factor Binding Protein 1; modulates fibroblast growth factor activity.
<i>CXCL8</i>	1.306	4.189E-42	3.228E-40	Chemokine (C-X-C motif) Ligand 8; is a pro-inflammatory cytokine is involved in immune response.
<i>HERPUD1</i>	-1.177	6.225E-37	3.950E-35	Homocysteine-Inducible, Endoplasmic Reticulum Stress-Inducible, Ubiquitin-Like Domain 1; involves in the unfolded protein response.
<i>RETREG3</i>	-0.867	2.697E-35	1.637E-33	Reticulophagy Regulator 3; possibly is involved in autophagy or cell survival.
<i>PRXL2A</i>	-0.585	7.438E-32	3.890E-30	Peroxiredoxin-Like 2A; is involved in oxidative stress response.
<i>SDR42E1</i>	-1.137	1.981E-29	9.168E-28	Short Chain Dehydrogenase/Reductase Family 42E, 1; potential role in steroid metabolism.
<i>ADAR</i>	-0.467	3.532E-27	1.448E-25	Adenosine Deaminase Acting on RNA; is involved in RNA editing.
<i>ZPR1</i>	0.634	1.190E-25	4.498E-24	ZPR1 Zinc Finger; essential for cell viability and may play a role in cell proliferation.
<i>ARNT</i>	-0.734	2.807E-19	7.197E-18	Aryl Hydrocarbon Receptor Nuclear Translocator; is involved in response to environmental toxins.
<i>BCL11A</i>	-1.658	5.743E-17	1.276E-15	BAF Chromatin Remodeling Complex Subunit BCL11A; a transcription factor is involved in hematopoietic development.
<i>TRPS1</i>	-3.028	1.862E-15	3.668E-14	TRPS1 Transcription Repressor; is involved in skeletal development.
<i>KIF20B</i>	-0.403	5.962E-15	1.134E-13	Kinesin Family 20B; is involved in mitosis and cell division.
<i>RABGAP1</i>	-0.417	1.898E-10	2.341E-09	RAB GTPase Activating Protein 1; is involved in intracellular membrane trafficking.
<i>GNAQ</i>	-0.395	7.397E-10	8.351E-09	G Protein Subunit Alpha Q; a component of a signaling pathway is involved in various cell processes.
<i>CYP26A1</i>	-1.55	9.489E-10	1.054E-08	Cytochrome P450 Family 26 Subfamily A1; is involved in vitamins metabolism.

<i>CARMIL1</i>	-0.390	2.820E-09	2.936E-08	Capping Protein Regulator and Myosin 1 Linker 1; is involved in cell migration and adhesion.
<i>ATP1B3</i>	-0.312	3.532E-09	3.618E-08	ATPase Na+/K+ Transporting Subunit Beta 3; is involved in ion transport.
<i>DHCR7</i>	0.406	8.034E-09	7.869E-08	7-Dehydrocholesterol Reductase; is involved in cholesterol and steroid biosynthesis.
<i>ZNF587B</i>	0.456	1.458E-08	1.369E-07	Zinc Finger Protein 587B; likely a transcription factor.
<i>ASH1L</i>	-0.337	1.510E-08	1.415E-07	ASH1 Like Histone Lysine Methyltransferase; is involved in chromatin modification.
<i>DOCK8</i>	-3.042	2.127E-07	1.687E-06	Dedicator Of Cytokinesis 8; is involved in immune cell signaling and function.
<i>GALNT2</i>	-0.307	2.218E-07	1.754E-06	Polypeptide N-Acetylgalactosaminyltransferase 2; is involved in glycosylation.
<i>SMYD3</i>	-0.755	5.670E-07	4.180E-06	SET And MYND Domain Containing 3; a histone methyltransferase is involved in chromatin regulation.
<i>KLK10</i>	-0.394	2.198E-06	1.45E-05	Kallikrein Related Peptidase 10; is involved in proteolysis and various physiological processes.
<i>CELSR2</i>	-0.421	2.214E-06	1.46E-05	Cadherin EGF LAG Seven-Pass G-Type Receptor 2; is involved in cell adhesion and signaling.
<i>ZNF680</i>	-0.820	5.506E-06	3.37E-05	Zinc Finger Protein 680; likely functions as a transcription factor.
<i>USP3</i>	0.330	6.418E-06	3.88E-05	Ubiquitin Specific Peptidase 3; is involved in DNA damage response and repair.
<i>FTO</i>	-0.344	8.016E-06	4.77E-05	FTO Alpha-Ketoglutarate Dependent Dioxygenase; associated with body mass and obesity.
<i>MCUB</i>	-0.599	9.294E-06	5.46E-05	Mitochondrial Calcium Uniporter, MCUb Subunit; is involved in mitochondrial calcium uptake.
<i>MAN2A1</i>	-0.236	1.51E-05	8.52E-05	Mannosidase Alpha Class 2A 1; is involved in glycoprotein processing.
<i>TRMT61A</i>	0.419	1.88E-05	0.0001046	tRNA Methyltransferase 61A; is involved in tRNA modification.
<i>BTBD10</i>	0.296	3.22E-05	0.0001702	BTB Domain Containing 10; potentially is involved in neuronal survival and apoptosis.

Genes listed associated with vitamin D at P -values $< 5E-05$ and reported in the GWAS Catalog for vitamin D with P -values $< 5E-08$. Abbreviations: Log₂ FC, Log₂ Fold Change estimate; FDR, false discovery rate represents adjusted P -value using the Benjamini-Hochberg in DESeq2.

503 **References**

- 504 1. Hypponen, E., K.S. Vimalaswaran, and A. Zhou, *Genetic Determinants of 25-*
505 *Hydroxyvitamin D Concentrations and Their Relevance to Public Health*. *Nutrients*,
506 2022. **14**(20).
- 507 2. Hendi, N.N., et al., *Genetic determinants of Vitamin D deficiency in the Middle Eastern*
508 *Qatari population: a genome-wide association study*. *Front Nutr*, 2023. **10**: p. 1242257.
- 509 3. Ogunmwonyi, I., A. Adebajo, and J.M. Wilkinson, *The genetic and epigenetic*
510 *contributions to the development of nutritional rickets*. *Front Endocrinol (Lausanne)*,
511 2022. **13**: p. 1059034.
- 512 4. Sinnott-Armstrong, N., et al., *Genetics of 35 blood and urine biomarkers in the UK*
513 *Biobank*. *Nat Genet*, 2021. **53**(2): p. 185-194.
- 514 5. Revez, J.A., et al., *Genome-wide association study identifies 143 loci associated with 25*
515 *hydroxyvitamin D concentration*. *Nat Commun*, 2020. **11**(1): p. 1647.
- 516 6. Qiu, S., et al., *Genetic correlation, causal relationship, and shared loci between vitamin*
517 *D and COVID-19: A genome-wide cross-trait analysis*. *J Med Virol*, 2023. **95**(5): p.
518 e28780.
- 519 7. Persson, B., et al., *The SDR (short-chain dehydrogenase/reductase and related enzymes)*
520 *nomenclature initiative*. *Chem Biol Interact*, 2009. **178**(1-3): p. 94-8.
- 521 8. Hendi, N.N. and G. Nemer, *In silico characterization of the novel SDR42E1 as a*
522 *potential vitamin D modulator*. *J Steroid Biochem Mol Biol*, 2023. **238**: p. 106447.
- 523 9. Loveland, J.L., D.B. Lank, and C. Kupper, *Gene Expression Modification by an*
524 *Autosomal Inversion Associated With Three Male Mating Morphs*. *Front Genet*, 2021. **12**:
525 p. 641620.
- 526 10. Bouhouche, A., et al., *Identification of the novel SDR42E1 gene that affects steroid*
527 *biosynthesis associated with the oculocutaneous genital syndrome*. *Exp Eye Res*, 2021.
528 **209**: p. 108671.
- 529 11. Chen, S., et al., *Gonadotropin inhibitory hormone downregulates steroid hormone*
530 *secretion and genes expressions in duck granulosa cells*. *Anim Reprod*, 2021. **18**(2): p.
531 e20210036.
- 532 12. Stiles, A.R., et al., *Genetic, anatomic, and clinical determinants of human serum sterol*
533 *and vitamin D levels*. *Proc Natl Acad Sci U S A*, 2014. **111**(38): p. E4006-14.
- 534 13. Liu, W., et al., *Assays of plasma dehydrocholesteryl esters and oxysterols from Smith-*
535 *Lemli-Opitz syndrome patients*. *J Lipid Res*, 2013. **54**(1): p. 244-53.
- 536 14. Tomita, H., et al., *7-Dehydrocholesterol-derived oxysterols cause neurogenic defects in*
537 *Smith-Lemli-Opitz syndrome*. *Elife*, 2022. **11**.
- 538 15. Lachmann, A., et al., *Massive mining of publicly available RNA-seq data from human*
539 *and mouse*. *Nat Commun*, 2018. **9**(1): p. 1366.
- 540 16. Sanjana, N.E., O. Shalem, and F. Zhang, *Improved vectors and genome-wide libraries for*
541 *CRISPR screening*. *Nat Methods*, 2014. **11**(8): p. 783-784.
- 542 17. Kingston, R.E., C.A. Chen, and H. Okayama, *Calcium phosphate transfection*. *Curr*
543 *Protoc Cell Biol*, 2003. **Chapter 20**: p. Unit 20 3.
- 544 18. Livak, K.J. and T.D. Schmittgen, *Analysis of relative gene expression data using real-*
545 *time quantitative PCR and the 2(-Delta Delta C(T)) Method*. *Methods*, 2001. **25**(4): p.
546 402-8.

- 547 19. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and*
548 *dispersion for RNA-seq data with DESeq2*. *Genome Biol*, 2014. **15**(12): p. 550.
- 549 20. Luo, W. and C. Brouwer, *Pathview: an R/Bioconductor package for pathway-based data*
550 *integration and visualization*. *Bioinformatics*, 2013. **29**(14): p. 1830-1.
- 551 21. Wu, T., et al., *clusterProfiler 4.0: A universal enrichment tool for interpreting omics*
552 *data*. *Innovation (Camb)*, 2021. **2**(3): p. 100141.
- 553 22. Wu, H., et al., *DrugSig: A resource for computational drug repositioning utilizing gene*
554 *expression signatures*. *PLoS One*, 2017. **12**(5): p. e0177743.
- 555 23. Yoo, M., et al., *DSigDB: drug signatures database for gene set analysis*. *Bioinformatics*,
556 2015. **31**(18): p. 3069-71.
- 557 24. Sollis, E., et al., *The NHGRI-EBI GWAS Catalog: knowledgebase and deposition*
558 *resource*. *Nucleic Acids Res*, 2023. **51**(D1): p. D977-D985.
- 559 25. Dekker, J., et al., *Spatial analysis of the ancient proteome of archeological teeth using*
560 *mass spectrometry imaging*. *Rapid Commun Mass Spectrom*, 2023. **37**(8): p. e9486.
- 561 26. Schindelin, J., et al., *Fiji: an open-source platform for biological-image analysis*. *Nat*
562 *Methods*, 2012. **9**(7): p. 676-82.
- 563 27. Amrein, K., et al., *Vitamin D deficiency 2.0: an update on the current status worldwide*.
564 *Eur J Clin Nutr*, 2020. **74**(11): p. 1498-1513.
- 565 28. He, X.Y., et al., *Characterization and localization of human type10 17beta-*
566 *hydroxysteroid dehydrogenase*. *Eur J Biochem*, 2001. **268**(18): p. 4899-907.
- 567 29. Hu, J., et al., *Cellular cholesterol delivery, intracellular processing and utilization for*
568 *biosynthesis of steroid hormones*. *Nutr Metab (Lond)*, 2010. **7**: p. 47.
- 569 30. Shaheen, S., S.S. Noor, and Q. Barakzai, *Serum alkaline phosphatase screening for*
570 *vitamin D deficiency states*. *J Coll Physicians Surg Pak*, 2012. **22**(7): p. 424-7.
- 571 31. Peach, H., et al., *Value of plasma calcium, phosphate, and alkaline phosphatase*
572 *measurements in the diagnosis of histological osteomalacia*. *J Clin Pathol*, 1982. **35**(6): p.
573 625-30.
- 574 32. Kovar, I., P. Mayne, and D. Barltrop, *Plasma alkaline phosphatase activity: a screening*
575 *test for rickets in preterm neonates*. *Lancet*, 1982. **1**(8267): p. 308-10.
- 576 33. Aly, Y.F., M.A. El Koumi, and R.N. Abd El Rahman, *Impact of maternal vitamin D*
577 *status during pregnancy on the prevalence of neonatal vitamin D deficiency*. *Pediatr Rep*,
578 2013. **5**(1): p. e6.
- 579 34. Misra, M., et al., *Vitamin D deficiency in children and its management: review of current*
580 *knowledge and recommendations*. *Pediatrics*, 2008. **122**(2): p. 398-417.
- 581 35. Buniello, A., et al., *The NHGRI-EBI GWAS Catalog of published genome-wide*
582 *association studies, targeted arrays and summary statistics 2019*. *Nucleic Acids Res*,
583 2019. **47**(D1): p. D1005-D1012.
- 584 36. Van den Broeck, T., et al., *The role of single nucleotide polymorphisms in predicting*
585 *prostate cancer risk and therapeutic decision making*. *Biomed Res Int*, 2014. **2014**: p.
586 627510.
- 587 37. Hyland, P.L., et al., *Genetic variants in sex hormone metabolic pathway genes and risk of*
588 *esophageal squamous cell carcinoma*. *Carcinogenesis*, 2013. **34**(5): p. 1062-8.
- 589 38. Choi, Y.J., et al., *Publisher Correction: SERPINB1-mediated checkpoint of inflammatory*
590 *caspase activation*. *Nat Immunol*, 2019. **20**(5): p. 664.

- 591 39. Toderici, M., et al., *Correction: Identification of Regulatory Mutations in SERPINC1*
592 *Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency*. PLoS
593 One, 2016. **11**(7): p. e0159987.
- 594 40. Lu, J., et al., *Transcriptional profiling of keratinocytes reveals a vitamin D-regulated*
595 *epidermal differentiation network*. J Invest Dermatol, 2005. **124**(4): p. 778-85.
- 596 41. Tomic, M., et al., *Nuclear receptors for retinoic acid and thyroid hormone regulate*
597 *transcription of keratin genes*. Cell Regul, 1990. **1**(12): p. 965-73.
- 598 42. Yan, X., et al., *Knockdown of KRT17 decreases osteosarcoma cell proliferation and the*
599 *Warburg effect via the AKT/mTOR/HIF1alpha pathway*. Oncol Rep, 2020. **44**(1): p. 103-
600 114.
- 601 43. El Ansari, R., et al., *The amino acid transporter SLC7A5 confers a poor prognosis in the*
602 *highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B*
603 *tumours*. Breast Cancer Res, 2018. **20**(1): p. 21.
- 604 44. Park, G., et al., *l-Type amino acid transporter 1 in hypothalamic neurons in mice*
605 *maintains energy and bone homeostasis*. JCI Insight, 2023. **8**(7).
- 606 45. Ozaki, K., et al., *The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and*
607 *maintains bone homeostasis through the mTORC1 pathway*. Sci Signal, 2019. **12**(589).
- 608 46. Jia, X., et al., *Vitamin D stimulates placental L-type amino acid transporter 1 (LAT1) in*
609 *preeclampsia*. Sci Rep, 2022. **12**(1): p. 4651.
- 610 47. Tsumura, H., et al., *Conditional deletion of CD98hc inhibits osteoclast development*.
611 Biochem Biophys Rep, 2016. **5**: p. 203-210.
- 612 48. Li, Q., et al., *Carnobacterium maltaromaticum boosts intestinal vitamin D production to*
613 *suppress colorectal cancer in female mice*. Cancer Cell, 2023. **41**(8): p. 1450-1465 e8.
614

615

616

617

618

619

620

621

622

623

624

625

626

627

628 **Figure 1** Transient protein and transcript expression of SDR42E1 in gene-edited and wild-type HaCat cells.

629 **a**, Immunoblotting of protein extracts from wild-type HaCat cells (lane 1) and cells with transient overexpression of
630 wild-type SDR42E1-HA (44 kDa; lane 2, indicated by a red arrow) was performed using rabbit SDR42E1-tag
631 polyclonal antibody at a 1:1000 dilution. Ponceau-S Red staining (PonS) served as a loading control. **b**, HaCat cells
632 with wild-type SDR42E1 expression (green) were stained overnight with rabbit α HA-tag polyclonal antibody at a
633 1:100 dilution, with nuclear localization revealed by Hoechst (blue). Cells were transiently transfected with a 5-
634 microgram SDR42E1-HA tagged plasmid for 24 hours. **c**, WB analysis of immunoprecipitated SDR42E1 in whole
635 protein lysate derived from the gene-edited HaCat cells of clone 32 (SDR42E1-KO-32) revealed the absence of a 44
636 kDa band corresponding to SDR42E1 (highlighted by a red arrow) using rabbit SDR42E1 polyclonal antibody (PA5-
637 53156, Invitrogen). Before the IP experiments, one-tenth of total lysates were subjected to the respective WB as input
638 controls using an anti-beta-actin mouse antibody (A5441, Sigma, 1:5000 dilution). Ctrl-Cas9 is an untargeted sgRNA-
639 Cas9 vector in HaCat as a negative control. **d**, RT-qPCR analysis revealed significantly decreased *SDR42E1* transcript
640 expression in *SDR42E1*-KO-32 compared to controls (Ctrl-Cas9). The relative expression level of *SDR42E1* was
641 normalized by the internal control β -actin. Data represent the mean \pm standard deviation of three replicates, with
642 similar results and significant differences relative to Cas9 control were analyzed by t-test with $p < 0.0001$ (****).

643 **Figure 2** Extensive alterations in gene expressions in the *SDR42E1* knockout model

644 **a**, A PCA plot demonstrates the clustering of three biological replicates of wild-type HaCat controls (C; in rose) and
645 *SDR42E1* homozygous knockouts (Hom, in blue), through the major principal components of the regularized log-
646 transformed counts. **b**, An MDS plot illustrates the correlation between \log_2 fold change and the mean of the
647 normalized counts in *SDR42E1* knockouts, with significant DEG highlighted in blue (adjusted P -value < 0.05). **c**, A
648 volcano plot depicts significant gene expression changes in *SDR42E1* knockouts compared to wild-type controls. The
649 X-axis displays the \log_2 fold change (FC), with upregulated genes to the right and downregulated to the left, while the
650 Y-axis represents the false discovery rate (FDR). Points represent individual genes with detectable expression changes,
651 meeting the criteria of an adjusted P -value < 0.05 and a $\text{Log}_2\text{FC} > 1$, with the top 20 most significantly altered genes
652 labeled. **d**, A cluster heatmap shows the Z-scores of regularized log-transformed counts for the top 100 DEG, with
653 blue indicating lower and red indicating higher expression, highlighting the distinct separation of sample conditions.

654 The X- and Y-axes are labeled with sample names and DEGs, respectively. All analyses were conducted and visualized
655 using R/DESeq2 and Pheatmap.

656 **Figure 3** Extensive alterations in gene pathways in the *SDR42E1* knockout model

657 **a**, A dot plot illustrates enriched KEGG pathways for DEG. The Y-axis represents the KEGG pathways; the X-axis
658 represents the ratio of the genes enriched in the KEGG pathway. A KEGG pathway diagram, enhanced via the
659 R/Pathview package, shows the expression profiles of genes involved in **b**, steroid biosynthesis and **c**, in steroid
660 hormone biosynthesis. Red indicates genes upregulated, while green denotes genes downregulated by the *SDR42E1*
661 knockout. **d**, A bar plots of signature drugs associated with *SDR42E1* knockout through DSigDB. The color and size
662 of dots and bars reflect the significance and count of DEG linked to KEGG pathways and drugs, respectively. *P*-value
663 adjusted ($p. \text{adjust}$) < 0.05 was used as the threshold to select KEGG terms.

664 **Figure 4** Extensive alterations in protein expressions and pathways in the *SDR42E1* knockout model

665 **a**, A PCA plot reveals the clustering of three biological replicates of wild-type HaCat controls (C; in rose) and
666 *SDR42E1* homozygous knockouts (Hom, in blue), based on the major components of regularized log-transformed
667 counts. **b**, A heatmap displays the Z-scores of log-transformed counts for the top 100 differentially expressed proteins,
668 using blue to indicate lower and red for higher expression, highlighting clear separation between samples. Axes are
669 labeled with sample names and proteins. **c**, A volcano plot compares the proteomic data of homozygous *SDR42E1*
670 knockout cells to wild-type HaCat controls. The X-axis shows \log_2 fold change (FC), with significant upregulation to
671 the right (greater than 1) and downregulation to the left (less than -1). The Y-axis shows the $-\log$ of the false discovery
672 rate (FDR), marking significance below 0.05. The top 20 significantly altered proteins are highlighted. **d**, A GSE dot
673 plot presents pathway enrichment analysis of the differentially expressed proteins in *SDR42E1* homozygous
674 knockouts. These analyses were conducted and visualized using R/Limma, Pheatmap, and ClusterProfiler.

675 **Figure 5** Decreased vitamin D levels in the *SDR42E1* knockout model.

676 Vitamin D levels in the *SDR42E1* knockout model was measured with a vitamin D ELISA assay. Compared to wild-
677 type HaCat cells, the knockout model showed significantly reduced vitamin D levels across three replicated
678 experiments (**; *P*-value < 0.01).





679 **Figure 6** Potential role of *SDR42E1* in Vitamin D Biosynthesis and Regulation.





680 The pathway illustrates the influence of *SDR42E1* absence in vitamin D skin synthesis from 7-DHC upon solar
681 ultraviolet B (UVB) exposure. To boost vitamin D levels, the body increases the conversion of 8-DHC or cholesterol





682 to 7-DHC by upregulating enzymes EBP or DHCR7. Intestinal absorption of vitamin D is also improved by the
683 upregulation of ABCB1. The liver then enhances the conversion to 25(OH)D by upregulating CYP27A1 or CYP3A4,
684 and the kidneys increase activation to 1,25-dihydroxyvitamin D via CYP27B1 upregulation, regulating related-gene
685 expressions via vitamin D receptor (VDR)/retinoid-X receptor (RXR) complex. The inactivation and secretion
686 process, usually facilitated by the CYP24A1 enzyme, is also diminished. Red indicates proteins upregulated, while
687 green denotes proteins downregulated by the SDR42E1 absence. (?) indicates our proposed SDR42E1 involvement in
688 vitamin D biosynthesis. 2D chemical structures obtained from PubChem: <https://pubchem.ncbi.nlm.nih.gov>.
689 Generated with BioRender.com.





690


Journal Pre-proof




a**b****c****d**

a**b****c****d**







Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Journal Pre-proof